NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first...
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration....
SUZHOU, China, March 31, 2025 /PRNewswire/ -- On 26 March, Suzhou Pudu Co-Intelligence Technology Company, a joint venture between Xi'an Jiaotong-Liverpool University (XJTLU) and Baidu Group,...
